Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvyn Lynn

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Antimicrobial Agents and Chemotherapy|August 26, 2003
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrationsKishor M Wasan, Olena Sivak, Richard A Cote, et al.
Pharmaceutical Research|September 13, 2007
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbitsKishor M Wasan, Verica Risovic, Olena Sivak, et al.
Innate Immunity|March 31, 2012
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian menNaoki Aikawa, Yoshio Okubo, Melvyn Lynn, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2003
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]Melvyn Lynn, Y Nancy Wong, Janice L Wheeler, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Antimicrobial Agents and Chemotherapy|August 26, 2003
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrationsKishor M Wasan, Olena Sivak, Richard A Cote, et al.
Pharmaceutical Research|September 13, 2007
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbitsKishor M Wasan, Verica Risovic, Olena Sivak, et al.
Innate Immunity|March 31, 2012
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian menNaoki Aikawa, Yoshio Okubo, Melvyn Lynn, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 21, 2003
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected]Melvyn Lynn, Y Nancy Wong, Janice L Wheeler, et al.
JAMA|March 21, 2013
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trialSteven M Opal, Pierre-Francois Laterre, Bruno Francois, et al.
Pageof 2